Tenaya Therapeutics, Inc. (TNYA) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small mol...
Analysis Summary
Trailing-twelve-month margins: gross margin 263.7%, operating margin -79.3%, net margin -77.2%.
At the current price of $0.66, TNYA has negative trailing earnings (P/E not meaningful) and an ROE of -108.05%. Market capitalisation stands at $143M.
Balance sheet quality for TNYA: current ratio of 6.8, net cash position of $89.7M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $0.66 |
| Market Cap | $143M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.05 |
| EV / EBITDA | -0.77 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -108.05% |
| Return on Invested Capital | -136.78% |
| Return on Assets | -110.24% |
| Gross Margin | 263.67% |
| Operating Margin | -7929.89% |
| Net Margin | -7723.97% |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 4.52 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -4.36 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| TNYA | Tenaya Therapeutics, Inc. | $143M | 2.05 | -108.0% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -5.84% |
| 3 months | -9.98% |
| Year-to-date | -7.56% |
| 1 year | -46.09% |
| 3 years | -77.51% |
| 5 years | -96.85% |
52-Week Range
| 52-week High | $2.35 |
| 52-week Low | $0.53 |
| Avg Volume (90d) | 2.8M |
Related companies: ABEO · CRBU · ENTA · FHTX · HUMA · IMRX · NAUT
Explore sector: Healthcare · Biotechnology
More sections of TNYA: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks